BioLineRx (BLRX) vs Senti Biosciences (SNTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioLineRx (BLRX) has outperformed Senti Biosciences (SNTI) over the past year, losing 49.8% versus a loss of 81.9%. Over five years, BLRX leads with a -98.2% price change compared with -99.7% for SNTI. BioLineRx is the larger company by market cap ($11.0 million vs $10.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLRX | SNTI |
|---|---|---|
| Share price | $2.21 | $0.3217 |
| Market cap | $11.00M | $10.02M |
| 1-day change | +0.23% | -2.52% |
| YTD return | -20.22% | -69.07% |
| 1-year return | -49.77% | -81.93% |
| 5-year return | -98.19% | -99.68% |
| EPS (TTM) | $0.00 | $-1.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.50 | $2.88 |
| 52-week low | $2.15 | $0.29 |
| Distance from 52-week high | -50.89% | -88.83% |
| Analyst consensus | none | none |
| Avg. price target upside | +895.48% | +4096.46% |
| Average volume | 16.27K | 573.78K |
| Shares outstanding | 4.98M | 31.15M |
| Employees | 20 | 39 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BLRX has outperformed SNTI by 32.2 percentage points over the past year.
About BioLineRx
BLRX stock →BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Healthcare · Biotechnology · 20 employees
About Senti Biosciences
SNTI stock →Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Healthcare · Biotechnology · 39 employees
BLRX vs SNTI FAQ
Which is bigger, BioLineRx or Senti Biosciences?
BioLineRx (BLRX) is larger, with a market capitalization of $11.00M compared with $10.02M for Senti Biosciences (SNTI).
Which stock has performed better over the past year, BLRX or SNTI?
BLRX returned -49.77% over the past 12 months, compared with -81.93% for SNTI (price return, excluding dividends). Past performance does not predict future results.
Are BioLineRx and Senti Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.